Objective： To evaluate the effects of gemcitabine on the microvessel density （MVD） and apoptosis in radiotherapy of cervical cancer. Methods： Forty-seven patients with locally advanced cervical cancer （ⅡB, Ⅲ an...Objective： To evaluate the effects of gemcitabine on the microvessel density （MVD） and apoptosis in radiotherapy of cervical cancer. Methods： Forty-seven patients with locally advanced cervical cancer （ⅡB, Ⅲ and IVA stage） were divided into two groups randomly： group A, 22 cases receiving radiotherapy combined with gemcitabine; group B, 25 cases receiving radiotherapy only. Tissue specimens were obtained from cervical tumor of all patients before and 24 h after radiotherapy with 10 Gy. MVD and apoptosis was detected by immunohistochemical staining and TUNEL assay respectively. Results： MVD （median） in group A was significantly reduced as compared with group B （P=0.001）. A-LI （median） in group A was significantly increased as compared with group B （P=0.034）. T0.5 in group A was significantly shorter than that in group B （P=0.018）. The reduction of MVD in group A was negatively correlated with T0.5 （r=-0.628）. There was no significant difference in gastrointestinal and haematological adverse effects between group A and group B. Conclusion： Gemcitabine, a novel potential radiosensitizer, can decrease the neoangiogenesis, increase the apoptosis in the early stage of radiotherapy of cervical cancer.展开更多
文摘Objective： To evaluate the effects of gemcitabine on the microvessel density （MVD） and apoptosis in radiotherapy of cervical cancer. Methods： Forty-seven patients with locally advanced cervical cancer （ⅡB, Ⅲ and IVA stage） were divided into two groups randomly： group A, 22 cases receiving radiotherapy combined with gemcitabine; group B, 25 cases receiving radiotherapy only. Tissue specimens were obtained from cervical tumor of all patients before and 24 h after radiotherapy with 10 Gy. MVD and apoptosis was detected by immunohistochemical staining and TUNEL assay respectively. Results： MVD （median） in group A was significantly reduced as compared with group B （P=0.001）. A-LI （median） in group A was significantly increased as compared with group B （P=0.034）. T0.5 in group A was significantly shorter than that in group B （P=0.018）. The reduction of MVD in group A was negatively correlated with T0.5 （r=-0.628）. There was no significant difference in gastrointestinal and haematological adverse effects between group A and group B. Conclusion： Gemcitabine, a novel potential radiosensitizer, can decrease the neoangiogenesis, increase the apoptosis in the early stage of radiotherapy of cervical cancer.
